OverviewInvestment HighlightsGalleryLocationContactSign the Agreement
Listing provided by LightBox Revere
18408-18412 Oxnard StTarzana, CA 91356
AstraZeneca
Asset ClassOffice, Mixed Use
Overview
Jones Lang LaSalle Americas, Inc. (“JLL”), as exclusive advisor, is pleased to present qualified investors the opportunity to acquire the 100% fee simple interest in AstraZeneca Labs (the “Property”), a state of-the-art, 128,097-square-foot cGMP and advanced manufacturing facility at 18408–18412 Oxnard Street in Los Angeles, California.
Investment Highlights
- 100% leased to AstraZeneca, an A+ / A1 rated, $260 billion global pharmaceutical company, with five credit rating upgrades since 2021
- 12.6 years of NNN lease term. AstraZeneca reimburses all operating expenses, taxes and insurance
- Mission-critical facility serving as one of two sites in AstraZeneca’s $50 billion U.S. investment plan, with $14M invested since 2024, and $9M more planned
- Generational opportunity to acquire a cGMP and advanced manufacturing facility well below replacement cost, built in 2020–2023 for $172M ($1,341/RSF)
- No near-term capital expected. AstraZeneca maintains all building systems, parking and the roof covering; the landlord is responsible only for structure
- Immediate access to power: a 4,000a, 480V service, a 2 MWbackup generator and a 1,100-ton chiller plant are already in place
- At the center of a $1 trillion economy with the largest manufacturing workforce of any U.S. county, where demand for manufacturing space far outpaces supply
Photo Gallery
18408-18412 Oxnard StTarzana, CA 91356
Sales Team
Jeff BramsonSenior Managing Director, Los Angeles Office Co-Head(312) 528-3687jeffrey.bramson@jll.com
Listing provided by LightBox Revere